AstraZeneca announced on February 13, 2026 that the Phase III KALOS and LOGOS trials of its triple‑combination inhaler BREZTRIAerosphere—containing budesonide, glycopyrronium, and formoterol fumarate—produced statistically significant and clinically meaningful improvements versus the standard inhaled corticosteroid/long‑acting beta‑agonist (ICS/LABA) regimen in patients with uncontrolled asthma.
The trials, published in The Lancet Respiratory Medicine, reported a 76 mL increase in forced expiratory volume in 1 second (FEV1) and a 90 mL rise in FEV1 area under the curve from 0 to 3 hours over 24 weeks. Annualized rates of severe exacerbations fell by 30 % compared with dual therapy, and no new safety signals were identified, confirming the drug’s tolerability profile.
These results represent the first Phase III evidence that BREZTRIAerosphere can benefit the 262 million people worldwide who remain uncontrolled on dual therapy. The data support a potential launch in the asthma market, expanding the drug’s current COPD indication and creating a new revenue stream for AstraZeneca’s respiratory portfolio, which already generated $58.7 billion in FY 2025 revenue.
The triple‑combination therapy positions BREZTRIAerosphere against a crowded field of dual‑combination inhalers and emerging triple‑therapy options, addressing a clear unmet need for patients who do not achieve control on standard care.
AstraZeneca’s CEO Pascal Soriot highlighted the company’s pipeline momentum, noting that the firm announced 16 positive Phase III studies in 2025 and now has 16 blockbuster medicines. The asthma data add to that momentum and reinforce the company’s strategy to transform respiratory care.
While no immediate market reaction to the announcement was reported, AstraZeneca’s shares had already risen 8 % since the Q4 2025 earnings release, and analysts continue to rate the company favorably, reflecting confidence in the company’s growth prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.